Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-02-15-Speech-2-579-000"
Predicate | Value (sorted: default) |
---|---|
rdf:type | |
dcterms:Date | |
dcterms:Is Part Of | |
dcterms:Language | |
lpv:document identification number |
"en.20110215.29.2-579-000"2
|
lpv:hasSubsequent | |
lpv:speaker | |
lpv:spokenAs | |
lpv:translated text |
"Madam President, Commissioner, in the light of this text, allow me to express my satisfaction and to emphasise one requirement and one point on which we will need to be vigilant.
I am pleased that we have succeeded in extending the legal basis for this directive from the original single market remit to cover public health too.
We have a requirement: we have fought to ensure that online sales form an integral part of this directive so as to be able to create checks and controls that reflect our findings.
There is also one point on which we will need to be vigilant. We know that falsified medicinal products make up 1% to 3% of the market in developed countries, between 10% and 30% in Asia and Latin America, and up to 70% in some African countries. Some studies suggest that trafficking falsified medicines can be 25 times more profitable than drug trafficking.
To summarise: we have successfully established one requirement and one point on which we need to remain vigilant if we are to continue to develop greater international cooperation, which, in turn, will allow the European Union to take the lead in the fight against the blight of falsified medicinal products.
I would like to thank Mrs Matias for her work and also our group’s rapporteur, Mrs Roth-Behrendt, who always provides valuable input in this field."@en1
|
lpv:videoURI |
Named graphs describing this resource:
The resource appears as object in 2 triples